{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:06:35Z","timestamp":1793261195299,"version":"4.5.0"},"reference-count":50,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T00:00:00Z","timestamp":1596326400000},"content-version":"unspecified","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008003","name":"Korea Institute of Radiological and Medical Sciences","doi-asserted-by":"publisher","award":["50461-2020"],"award-info":[{"award-number":["50461-2020"]}],"id":[{"id":"10.13039\/501100008003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008003","name":"Korea Institute of Radiological and Medical Sciences","doi-asserted-by":"publisher","award":["50536-2020"],"award-info":[{"award-number":["50536-2020"]}],"id":[{"id":"10.13039\/501100008003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002380","name":"Hanyang University","doi-asserted-by":"publisher","award":["HY-2011-G-201100000001880"],"award-info":[{"award-number":["HY-2011-G-201100000001880"]}],"id":[{"id":"10.13039\/501100002380","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2016M3A9B5942352"],"award-info":[{"award-number":["2016M3A9B5942352"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,6,24]]},"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Currently, several antibody (Ab)-based therapies have shown excellent therapeutic effects in the clinic. Nonetheless, Ab penetration into tumor tissues is limited due to abnormal vasculature, tumor interstitial pressure, and excessive extracellular matrix (ECM) accumulation, thus demanding novel strategies to overcome these barriers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The intratumoral distribution of therapeutic Abs were detected by fluorescence microscopy or positron emission tomography in both human gastric xenograft and syngeneic pancreatic hamster tumor models. The antitumor efficacy by combination of oncolytic adenovirus (Ad), which coexpresses relaxin (RLX), interleukin (IL)-12, and granulocyte macrophage colony-stimulating factor (GM-CSF) (oAd\/IL12\/GM-RLX) and antibody against the programmed cell death protein 1 (\u03b1PD-1) was examined in hamster subcutaneous and orthotopic pancreatic tumor models. The immunological aspects of these combination therapy regimen were assessed by flow cytometry or immunohistochemistry in subcutaneous hamster tumor models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Relaxin-expressing oncolytic Ad effectively degraded tumor ECM and enhanced the tumor penetration of trastuzumab in comparison with trastuzumab monotherapy. Based on these results, an oAd\/IL12\/GM-RLX was used to enhance the potency of immune checkpoint blockade. The combination of the oAd\/IL12\/GM-RLX and \u03b1PD-1 promoted a concomitant degradation of the tumor ECM and amelioration of the immunosuppressive tumor niches, ultimately enhanced intratumoral infiltration of both \u03b1PD-1 and activated T cells. Of note, the combination therapy was able to elicit a potent and durable antitumor immune response against cold tumors that were refractory to immune checkpoint inhibitor monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings are the first to demonstrate that expression of four genes (IL-12p35, IL-12p40, GM-CSF, and RLX) mediated by a single oncolytic Ad vector can promote remodeling of both physical and immunological aspects of the tumor niches to overcome the major limitations of Ab-based therapies that have emerged in recent clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2020-000763","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T08:50:22Z","timestamp":1596531022000},"page":"e000763","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":52,"title":["Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade"],"prefix":"10.1136","volume":"8","author":[{"given":"Bo-Kyeong","family":"Jung","sequence":"first","affiliation":[{"name":"Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Young","family":"Ko","sequence":"additional","affiliation":[{"name":"Division of RI Application, Korea Institute of Radiological and Medical Sciences, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunji","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of RI Application, Korea Institute of Radiological and Medical Sciences, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JinWoo","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Korea (the Republic of)"},{"name":"Department of Research and Development, GeneMedicine Co., Ltd, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Min","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Korea (the Republic of)"},{"name":"Department of Research and Development, GeneMedicine Co., Ltd, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youjin","family":"Na","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6990-3900","authenticated-orcid":false,"given":"Hyeongi","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of RI Application, Korea Institute of Radiological and Medical Sciences, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Su","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of RI Application, Korea Institute of Radiological and Medical Sciences, Seoul, Korea (the Republic of)"},{"name":"Radiological and Medico-Oncological Sciences, University of science and technology (UST), Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9466-4531","authenticated-orcid":false,"given":"Chae-Ok","family":"Yun","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Korea (the Republic of)"},{"name":"Department of Research and Development, GeneMedicine Co., Ltd, Seoul, Korea (the Republic of)"},{"name":"Institute of Nano Science and Technology (INST), Hanyang University, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,8,4]]},"reference":[{"key":"2025100314214980000_8.2.e000763.1","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2019.1703531","article-title":"Reichert JM: antibodies to watch in 2020","volume":"12","author":"Kaplon","year":"2020","journal-title":"MAbs"},{"key":"2025100314214980000_8.2.e000763.2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611693104"},{"key":"2025100314214980000_8.2.e000763.3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2013.00193","article-title":"Strategies to increase drug penetration in solid tumors","volume":"3","author":"Choi","year":"2013","journal-title":"Front Oncol"},{"key":"2025100314214980000_8.2.e000763.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2010.08.015"},{"key":"2025100314214980000_8.2.e000763.5","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.addr.2011.12.011","article-title":"Evolution of oncolytic adenovirus for cancer treatment","volume":"64","author":"Choi","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"2025100314214980000_8.2.e000763.6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.mce.2019.01.009","article-title":"Relaxin gene therapy: a promising new treatment option for various diseases with aberrant fibrosis or irregular angiogenesis","volume":"487","author":"Hong","year":"2019","journal-title":"Mol Cell Endocrinol"},{"key":"2025100314214980000_8.2.e000763.7","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.36"},{"key":"2025100314214980000_8.2.e000763.8","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxw014"},{"key":"2025100314214980000_8.2.e000763.9","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2762"},{"key":"2025100314214980000_8.2.e000763.10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/gt.2016.70","article-title":"Prime-Boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy","volume":"24","author":"Ilett","year":"2017","journal-title":"Gene Ther"},{"key":"2025100314214980000_8.2.e000763.11","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/1759-7714.13043","article-title":"Updates to the antitumor mechanism of oncolytic virus","volume":"10","author":"Bai","year":"2019","journal-title":"Thorac Cancer"},{"key":"2025100314214980000_8.2.e000763.12","doi-asserted-by":"crossref","DOI":"10.5306\/wjco.v8.i3.230","article-title":"Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations","volume":"8","author":"Guo","year":"2017","journal-title":"World J Clin Oncol"},{"key":"2025100314214980000_8.2.e000763.13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj397"},{"key":"2025100314214980000_8.2.e000763.14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/mt.2009.205","article-title":"Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL","volume":"18","author":"Huang","year":"2010","journal-title":"Mol Ther"},{"key":"2025100314214980000_8.2.e000763.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.06.025"},{"key":"2025100314214980000_8.2.e000763.16","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jconrel.2015.10.015","article-title":"Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model","volume":"220","author":"Na","year":"2015","journal-title":"J Control Release"},{"key":"2025100314214980000_8.2.e000763.17","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-12-1379"},{"key":"2025100314214980000_8.2.e000763.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2009.02.060"},{"key":"2025100314214980000_8.2.e000763.19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067512"},{"key":"2025100314214980000_8.2.e000763.20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.canlet.2017.03.009","article-title":"Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer","volume":"396","author":"Jung","year":"2017","journal-title":"Cancer Lett"},{"key":"2025100314214980000_8.2.e000763.21","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2011.125"},{"key":"2025100314214980000_8.2.e000763.22","doi-asserted-by":"crossref","unstructured":"Heatley JJ , Harris MC . Chapter 15 - Hamsters and Gerbils. In: Mitchell MA , Tully TN , eds. Manual of exotic PET practice. Saint Louis: W.B. Saunders, 2009: 406\u201332.","DOI":"10.1016\/B978-141600119-5.50018-4"},{"key":"2025100314214980000_8.2.e000763.23","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2008.80"},{"key":"2025100314214980000_8.2.e000763.24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/958560","article-title":"Lipid lowering effects of hydroalcoholic extract of Anethum graveolens L. and dill tablet in high cholesterol fed hamsters","volume":"2015","author":"Abbasi Oshaghi","year":"2015","journal-title":"Cholesterol"},{"key":"2025100314214980000_8.2.e000763.25","doi-asserted-by":"crossref","first-page":"41825","DOI":"10.18632\/oncotarget.9729","article-title":"Characterization and use of HapT1-derived homologous tumors as a preclinical model to evaluate therapeutic efficacy of drugs against pancreatic tumor desmoplasia","volume":"7","author":"Suklabaidya","year":"2016","journal-title":"Oncotarget"},{"key":"2025100314214980000_8.2.e000763.26","first-page":"360","article-title":"Pancreas adenocarcinoma: ascites, clinical manifestations, and management implications","volume":"15","author":"Hicks","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"2025100314214980000_8.2.e000763.27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.12382","article-title":"Enhancement of T cell recruitment and infiltration into tumours","volume":"178","author":"Oelkrug","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2025100314214980000_8.2.e000763.28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1741"},{"key":"2025100314214980000_8.2.e000763.29","doi-asserted-by":"crossref","DOI":"10.4161\/tisb.29528","article-title":"Barriers to drug delivery in solid tumors","volume":"2","author":"Sriraman","year":"2014","journal-title":"Tissue Barriers"},{"key":"2025100314214980000_8.2.e000763.30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1932"},{"key":"2025100314214980000_8.2.e000763.31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2018.09.031","article-title":"Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo","volume":"290","author":"Mardhian","year":"2018","journal-title":"J Control Release"},{"key":"2025100314214980000_8.2.e000763.32","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.18632\/oncotarget.13972","article-title":"Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model","volume":"8","author":"Oh","year":"2017","journal-title":"Oncotarget"},{"key":"2025100314214980000_8.2.e000763.33","doi-asserted-by":"publisher","DOI":"10.4137\/CMO.S34537"},{"key":"2025100314214980000_8.2.e000763.34","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1158\/1535-7163.1493.3.11","article-title":"Biological impediments to monoclonal antibody-based cancer immunotherapy","volume":"3","author":"Christiansen","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"2025100314214980000_8.2.e000763.35","first-page":"3183","article-title":"Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms","volume":"46","author":"Epenetos","year":"1986","journal-title":"Cancer Res"},{"key":"2025100314214980000_8.2.e000763.36","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22402"},{"key":"2025100314214980000_8.2.e000763.37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2009"},{"key":"2025100314214980000_8.2.e000763.38","article-title":"Enhanced therapeutic efficacy of iRGD-conjugated crosslinked multilayer liposomes for drug delivery","volume":"2013","author":"Liu","year":"2013","journal-title":"Biomed Res Int"},{"key":"2025100314214980000_8.2.e000763.39","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3696"},{"key":"2025100314214980000_8.2.e000763.40","first-page":"3776","article-title":"Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications","volume":"59","author":"Griffon-Etienne","year":"1999","journal-title":"Cancer Res"},{"key":"2025100314214980000_8.2.e000763.41","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.88"},{"key":"2025100314214980000_8.2.e000763.42","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-016-0365-1","article-title":"Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?","volume":"8","author":"O'Donnell","year":"2016","journal-title":"Genome Med"},{"key":"2025100314214980000_8.2.e000763.43","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0165-6"},{"key":"2025100314214980000_8.2.e000763.44","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0215"},{"key":"2025100314214980000_8.2.e000763.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2013.01.006"},{"key":"2025100314214980000_8.2.e000763.46","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11010039"},{"key":"2025100314214980000_8.2.e000763.47","doi-asserted-by":"crossref","unstructured":"Algazi A , Tsai KK , Takamura KT , et al . Le MH: Abstract CT134: intratumoral electroporation of plasmid IL-12 can prime response to anti-PD1\/PD-L1 blockade in patients with stage III\/IV-M1a melanoma. AACR 2016.","DOI":"10.1158\/1538-7445.AM2016-CT134"},{"key":"2025100314214980000_8.2.e000763.48","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501"},{"key":"2025100314214980000_8.2.e000763.49","doi-asserted-by":"crossref","unstructured":"Wong RM . Cameron RB: Immune Checkpoint Blockade and Adaptive Immune Resistance in Cancer. In Immunotherapy-Myths, Reality, Ideas, Future. InTech 2017.","DOI":"10.5772\/66494"},{"key":"2025100314214980000_8.2.e000763.50","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601145"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-000763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T21:22:01Z","timestamp":1759526521000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-000763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,8,4]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/jitc-2020-000763"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-000763","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}